295-64-7

Usage

Uses

Used in Coordination Chemistry:
1,4,7,10,13-Pentaazacyclopentadecane serves as a complexing agent, particularly for forming stable complexes with metal ions. Its ability to chelate metals enhances its utility in this field.
Used in Synthesis of Macrocyclic Ligands:
1,4,7,10,13-Pentaazacyclopentadecane is utilized in the synthesis of macrocyclic ligands, which are important in creating structures with specific binding properties.
Used in Chemical Analysis and Separation Processes:
As a chelating agent, 1,4,7,10,13-Pentaazacyclopentadecane aids in chemical analysis and separation processes, improving the efficiency and selectivity of these techniques.
Used in Medical Imaging:
1,4,7,10,13-Pentaazacyclopentadecane has potential applications in medical imaging, where its complexing abilities could enhance the contrast and specificity of imaging agents.
Used in Drug Delivery:
1,4,7,10,13-Pentaazacyclopentadecane is being explored for its use in drug delivery systems, potentially improving the targeting and release of therapeutic agents.
Used in Catalytic Systems:
1,4,7,10,13-Pentaazacyclopentadecane is a component in catalytic systems, where it may contribute to the efficiency and selectivity of chemical reactions.
Used in Materials Science:
In the field of materials science, 1,4,7,10,13-Pentaazacyclopentadecane is studied for its potential use in the development of molecular sieves and as a building block for self-assembled monolayers, showcasing its broad applicability in creating advanced materials.

InChI:InChI=1/C10H25N5/c1-2-12-5-6-14-9-10-15-8-7-13-4-3-11-1/h11-15H,1-10H2

Upstream product

• 52601-74-8 N¹,N⁴,N⁷,N¹⁰,N¹³-pentatosyl-1,4,7,10,13-penta-azacyclopentadecane 
• 56234-52-7 1,8-bis(p-toluenesulfonyloxy)-3,6-bis(p-toluenesulfonyl)-3,6-diazaoctane 
• 4439-20-7 N,N'-bis(2-hydroxyethyl)ethylene diamine 
• 55442-07-4 N,N',N'',N'''-tetrakis-(p-tolylsulphonyl)-triethylenetetramine 
• 112-24-3 triethylentetramine 

Downstream Products

• 85325-52-6 1,4,7,10,13-pentakis(2-hydroxyethyl)-1,4,7,10,13-pentaazacyclopentadecane 
• 126257-27-0 9-(1',4',7',10',13'-pentaazacyclopentadecyl)methylanthracene 
• 1879-55-6 (E)-1-nitro-4-(prop-1-en-1-yl)benzene 
• 354112-18-8 C₁₀H₂₄N₅CH₂-1,4-CH₂C₆H₄-C₅H₂N(C₅H₄N)2 
• 266000-49-1 1,4,7,10,13-pentakis(γ-aminobutylcarbonyl)-1,4,7,10,13-pentaaza-cyclopentadecane 
• 316147-15-6 [15]ane-N₅-(N-3-propyl)triethylammonium bromide hydrochloride 
• 131362-29-3 Ag({15}aneN₅)⁽²⁺⁾ 
• 82288-45-7 (Co(cpad)H₂O)⁽³⁺⁾ 

Relevant academic research and scientific papers

A convenient synthesis of 1,4,7,10,13-pentaazacyclopentadecane

Cyclic pentamine 1 was synthesized in good yields from fragments containing two and three nitrogen atoms.

Synthesis of N-quaternary ammonium [3H] and [(99m)Tc]Polyazamacrocycles, potential radiotracers for cartilage imaging

The [3H] and [(99m)Tc] synthesis of three new compounds, N-[3-(pyridinio)propyl] cyclam (NPPC), N-[3-(triethylammonium)propyl] cyclam (NTPC) and N-[3-(triethylammonium)propyl]-15ane-N5 (NTP 15-5), potential tracers for cartilage, is reported. NPPC and NTPC were labelled with tritium on the ethyl group of cyclam with a specific radioactivity of 89 MBq/mmol. The [(99m)Tc]-labelling of the three quaternary ammonium chelates was realized with a high specific activity in the range 20-25 MBq/μmol.

Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide

The present invention is directed to low molecular weight mimics of superoxide dismutase (SOD) represented by the formula: STR1 wherein R, R', R1, R'1, R2, R'2, R3, R'3, R4, R'4, R5, R'5, R6, R'6, R7, R'7, R8, R'8, R9, and R'9 and X, Y, Z and n are as defined herein, useful as therapeutic agents for inflammatory disease states and disorders, ischemic/reperfusion injury, stroke, atherosclerosis, hypertension and all other conditions of oxidant-induced tissue damage or injury.

Methods of preparing manganese complexes of nitrogen-containing macrocyclic ligands

The present invention is directed to low molecular weight mimics of superoxide dismutase (SOD) represented by the formula: STR1 wherein R, R', R1, R'1, R2, R'2, R3, R'3, R4, R'4, R5, R'5, R6, R'6, R7, R'7, R8, R'8, R9, and R'9 and X, Y, Z and n are as defined herein, useful as therapeutic agents for inflammatory disease states and disorders, ischemic/reperfusion injury, stroke, atherosclerosis, hypertension and all other conditions of oxidant-induced tissue damage or injury.

Cascade polymer bound chelating compounds, their chelates and conjugates, processes for their production, and pharmaceutical agents containing them

Cascade polymers, containing complex-forming ligands, optionally at least five ions of an element of atomic numbers 21-29, 39, 42, 44 or 57-83, as well as, if desired, cations of inorganic and/or organic bases, amino acids or amino acid amides, are valuable complexing compounds and complexes for diagnostics and therapy.

MACROHETEROCYCLES. 15.* SYNTHESIS OF MACROCYCLIC POLYAMINES IN A BIPHASIC SYSTEM

Macrocyclic polyamines are conveniently synthesized by condensation of bissulfonamides with ditosylates or dibromides of glycols in the biphasic system toluene(xylene)-aqueous sodium hydroxide.

Synthesis of macrocyclic polyamines: Application to the increase of urinary excretion of copper in rats

The properties of six chelating agents that form highly stable complexes with transition metals has been examined in a comparative study for the elimination of copper in rats. For cyclic ligands, effectiveness grows with the stability constants of their complexes with this metal. With respect to Trien L5 and Penicillamine L6, aliphalic ligands used in human therapy the 1,4,7,10,13-pentaazacyclopentadecane has proven to be more effective. After treatment by this macrocyclic polyamine, urinary excretion reached 60 times that observed in the control animals. The acute toxicity measurements in mice demonstrated that the intrinsically slightly toxic ligands are less so than their corresponding complexes. Considered in their entirety these results, with L2, permit the inference of an improvement in Wilson's disease therapy.

Macrocyclic polyamines

Macrocyclic polyamines containing 3-7 nitrogen atoms in the ring and destablized to complex formation by (1) an asymmetric ring and/or (2) provision of nitrogen atoms in excess of that required for complex formation are described. The compounds can be used to extract metal ions from solution. The metal complexes are thermally activated curing agents for epoxy resins.